Nctid:
NCT00000311
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D019966", "term"=>"Substance-Related Disorders"}, {"id"=>"D009293", "term"=>"Opioid-Related Disorders"}, {"id"=>"D019970", "term"=>"Cocaine-Related Disorders"}], "ancestors"=>[{"id"=>"D064419", "term"=>"Chemically-Induced Disorders"}, {"id"=>"D001523", "term"=>"Mental Disorders"}, {"id"=>"D000079524", "term"=>"Narcotic-Related Disorders"}], "browseLeaves"=>[{"id"=>"M21837", "name"=>"Substance-Related Disorders", "asFound"=>"Substance-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M12244", "name"=>"Opioid-Related Disorders", "asFound"=>"Opioid-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M21841", "name"=>"Cocaine-Related Disorders", "asFound"=>"Cocaine-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M30302", "name"=>"Chemically-Induced Disorders", "relevance"=>"LOW"}, {"id"=>"M14473", "name"=>"Psychotic Disorders", "relevance"=>"LOW"}, {"id"=>"M4815", "name"=>"Mental Disorders", "relevance"=>"LOW"}, {"id"=>"M2057", "name"=>"Narcotic-Related Disorders", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Substance Related Disorders", "abbrev"=>"BC25"}, {"name"=>"Behaviors and Mental Disorders", "abbrev"=>"BXM"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D002047", "term"=>"Buprenorphine"}, {"id"=>"D008691", "term"=>"Methadone"}], "ancestors"=>[{"id"=>"D000701", "term"=>"Analgesics, Opioid"}, {"id"=>"D009294", "term"=>"Narcotics"}, {"id"=>"D002492", "term"=>"Central Nervous System Depressants"}, {"id"=>"D045505", "term"=>"Physiological Effects of Drugs"}, {"id"=>"D000700", "term"=>"Analgesics"}, {"id"=>"D018689", "term"=>"Sensory System Agents"}, {"id"=>"D018373", "term"=>"Peripheral Nervous System Agents"}, {"id"=>"D009292", "term"=>"Narcotic Antagonists"}, {"id"=>"D000996", "term"=>"Antitussive Agents"}, {"id"=>"D019141", "term"=>"Respiratory System Agents"}], "browseLeaves"=>[{"id"=>"M5317", "name"=>"Buprenorphine", "asFound"=>"Group B", "relevance"=>"HIGH"}, {"id"=>"M4033", "name"=>"Analgesics, Opioid", "relevance"=>"LOW"}, {"id"=>"M11671", "name"=>"Methadone", "asFound"=>"Fluoride", "relevance"=>"HIGH"}, {"id"=>"M6271", "name"=>"Cocaine", "relevance"=>"LOW"}, {"id"=>"M4032", "name"=>"Analgesics", "relevance"=>"LOW"}, {"id"=>"M12245", "name"=>"Narcotics", "relevance"=>"LOW"}, {"id"=>"M12243", "name"=>"Narcotic Antagonists", "relevance"=>"LOW"}, {"id"=>"M13570", "name"=>"Phenylpropanolamine", "relevance"=>"LOW"}, {"id"=>"M9238", "name"=>"Guaifenesin", "relevance"=>"LOW"}, {"id"=>"M186319", "name"=>"Chlorpheniramine, phenylpropanolamine drug combination", "relevance"=>"LOW"}, {"id"=>"M4312", "name"=>"Antitussive Agents", "relevance"=>"LOW"}, {"id"=>"M21137", "name"=>"Respiratory System Agents", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Analgesics", "abbrev"=>"Analg"}, {"name"=>"Central Nervous System Depressants", "abbrev"=>"CNSDep"}, {"name"=>"Narcotic Antagonists", "abbrev"=>"NarcAntag"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Antitussive Agents", "abbrev"=>"AnTuAg"}, {"name"=>"Respiratory System Agents", "abbrev"=>"Resp"}, {"name"=>"Vasoconstrictor Agents", "abbrev"=>"VaCoAg"}, {"name"=>"Anti-Obesity Agents", "abbrev"=>"AnObAg"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE3"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"DOUBLE"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"FACTORIAL"}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>168}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1995-02"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2018-01", "completionDateStruct"=>{"date"=>"1999-02", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2018-01-12", "studyFirstSubmitDate"=>"1999-09-20", "studyFirstSubmitQcDate"=>"1999-09-20", "lastUpdatePostDateStruct"=>{"date"=>"2018-01-17", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"1999-09-21", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"1999-02", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Depression", "timeFrame"=>"24 weeks"}, {"measure"=>"Withdrawal symptoms"}, {"measure"=>"Opioid and cocaine use"}, {"measure"=>"Social and psychological functioning"}, {"measure"=>"AIDS risk behavior"}]}, "oversightModule"=>{"isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["Cocaine-Related Disorders", "Opioid-Related Disorders", "Substance-Related Disorders"], "conditions"=>["Cocaine-Related Disorders", "Opioid-Related Disorders", "Substance-Related Disorders"]}, "descriptionModule"=>{"briefSummary"=>"The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD", "ADULT", "OLDER_ADULT"], "healthyVolunteers"=>false, "eligibilityCriteria"=>"Please contact site for information."}, "identificationModule"=>{"nctId"=>"NCT00000311", "briefTitle"=>"Combining Behavioral Treatment With Agonist Maintenance - 1", "organization"=>{"class"=>"OTHER", "fullName"=>"Yale University"}, "officialTitle"=>"Combining Behavioral Treatment With Agonist Maintenance", "orgStudyIdInfo"=>{"id"=>"NIDA-09413-1"}, "secondaryIdInfos"=>[{"id"=>"R01DA009413", "link"=>"https://reporter.nih.gov/quickSearch/R01DA009413", "type"=>"NIH"}, {"id"=>"R01-09413-1"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"1", "description"=>"Methadone + CM (contingency management)", "interventionNames"=>["Drug: methadone"]}, {"type"=>"EXPERIMENTAL", "label"=>"2", "description"=>"methadone + VC (voucher control)", "interventionNames"=>["Drug: methadone"]}, {"type"=>"EXPERIMENTAL", "label"=>"3", "description"=>"Buprenorphine + CM", "interventionNames"=>["Drug: Buprenorphine"]}, {"type"=>"EXPERIMENTAL", "label"=>"4", "description"=>"Buprenorphine + VC", "interventionNames"=>["Drug: Buprenorphine"]}], "interventions"=>[{"name"=>"Buprenorphine", "type"=>"DRUG", "description"=>"Medication and Behavioral", "armGroupLabels"=>["3", "4"]}, {"name"=>"methadone", "type"=>"DRUG", "description"=>"medication and behavioral", "armGroupLabels"=>["1", "2"]}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"06519", "city"=>"New Haven", "state"=>"Connecticut", "country"=>"United States", "facility"=>"APT Residential Services Division", "geoPoint"=>{"lat"=>41.30815, "lon"=>-72.92816}}], "overallOfficials"=>[{"name"=>"Richard Schottenfeld, M.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"Yale University"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Yale University", "class"=>"OTHER"}, "collaborators"=>[{"name"=>"National Institute on Drug Abuse (NIDA)", "class"=>"NIH"}], "responsibleParty"=>{"oldNameTitle"=>"Richard S. Schottenfeld, MD", "oldOrganization"=>"Yale University School of Medicine"}}}}
